BridgeMD
Multicenter, controlled, randomized, observer-blinded clinical trial to evaluate the efficacy and safety of insulin eye drops (1 IU/ml) in the treatment of persistent corneal epithelial defect.
EU CTIS ID: 2024-518818-53-00
What this study is testing
To evaluate the efficacy of using insulin eye drops, comparing it with standard medical treatment (autologous serum eye drops), in the treatment of persistent epithelial defect of neurotrophic origin or secondary to chronic ocular surface diseases.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age over 18 years
- Diagnosis of persistent corneal epithelial defect
- Signature of informed consent
- Negative serology for HIV, HCV, HBV, HLTV and syphilis.
You likely can't join if
- Pregnancy or lactation
- Extreme stromal thinning (residual corneal thickness less than 60% of total corneal thickness).
- Severe limbal corneal ischaemia (grade IV or higher on the Dua scale, 6 hours or more of limbal ischaemia).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.